MindWalk Holdings Corp. operates as a biotechnology company focused on applying artificial intelligence and multi-omics data analysis to accelerate biologics discovery and development. The company develops and commercializes the LensAI platform and HYFT technology, which integrate computational biology with laboratory research to support pharmaceutical and biotechnology partners in drug development. Its service model centers on de-risking the development process for clients by leveraging AI-driven insights to identify and validate therapeutic targets.
The company generates revenue primarily through partnerships with pharmaceutical and biotechnology organizations seeking to streamline their discovery pipelines. These collaborative arrangements typically involve licensing access to its platforms and providing research services that combine AI analysis with wet-lab capabilities. The company maintains a relatively lean operational structure with 81 full-time employees and operates from its headquarters in Austin, Texas. MindWalk was incorporated in British Columbia, Canada in 1983 under its former name, ImmunoPrecise Antibodies Ltd., before rebranding to its current name in September 2025. The company trades on Nasdaq with a market capitalization of approximately $100 million.
No 10-K filings found.